Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Akriti Seth

Senior Reporter

London, UK
As a correspondent for Channel NewsAsia, Singapore and for India Technology News, Akriti has covered a wide range of subject-matter including politics, economics and technology for a B2B audience. She has also gained experience working for Bloomberg TV India and Mid-Day Mumbai. Akriti is a graduate of the University of Mumbai and holds a masters from Mumbai's Xavier Institute of Communications. Most recently she has worked as a freelance journalist in London, where she is now based, having lived there for the past two years. She enjoys photography and blogging.

Latest From Akriti Seth

Celltrion Sees Sales Dip In Q3

South Korea’s Celltrion delivered a relatively weak quarter in Q3, with a 26.9% drop in revenues despite robust sales of Truxima (rituximab) and Remsima (infliximab). The company also voiced confidence in pro-biosimilar policies introduced by the Biden administration in the US.

Sales & Earnings Biosimilars

Indian Regulatory And Industry Bodies Call For Open Dialog With Policymakers

The Indian Pharmaceutical Alliance’s recent Global Innovation Summit 2021 saw regulatory and industry bodies call for policy intervention to provide support and incentives for innovation and R&D in the Indian pharmaceutical sector. Inaugurated by the Indian prime minister Narendra Modi, the summit saw Modi invite “everyone to ideate in India, innovate in India and make in India and make for the world.”

Generic Drugs Biosimilars

JB Chemicals Sustains Revenue Momentum For Another Quarter

India’s JB Chemicals has seen double-digit growth in its international business and “market beating growth” in its domestic business. The company continues to perform well on the back of new launches, despite COVID-related headwinds. 

India International

Wockhardt’s UK Business Continues To Grow

Wockhardt’s UK segment continues to grow as the company records a 66% increase for the second quarter ending 30 September 2021. The company’s India market and Irish market performed well, while its emerging markets and US market failed to deliver. 

United Kingdom Deals

ANI Ready For Full-Scale Commercial Launch Of FDA-Approved Cortrophin Gel

ANI Pharmaceuticals has announced receiving the long-awaited FDA approval for its Cortrophin Gel and has plans for a full-scale commercial launch of the product in the first quarter of 2022. Meanwhile, ANI’s $210m acquisition of niche generics specialist Novitium Pharma is expected to close imminently.

Deals Generic Drugs

Fresenius Kabi To Build ‘One Of The Largest Sterile Injectable Manufacturing Networks In US’

Stating the importance of the US sterile injectables market for Fresenius Kabi, Matt Kuhn, senior director of external communications, talks to Generics Bulletin about the company’s plans to build one of the largest sterile injectable manufacturing networks in America. Meanwhile Ali Ahmed, senior vice president of biosimilars at Fresenius Kabi in the US, talks about supply reliability in biosimilars. 

Biosimilars Deals
See All
UsernamePublicRestriction

Register